Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Article Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
February 22, 2024
The process of discovering, producing, buying, and consuming antibiotics is riddled with market and government failures. To solve antibiotic resistance, it’s not enough to solve just some of these. If we fix the market failures that reduce the number of new antibiotics that are discovered, but not t...
WORKING PAPERS
February 22, 2024
Antibiotic resistance (ABR) already contributes to almost five million deaths per year. Without action, this number will likely rise substantially. We provide the first comprehensive assessment of the economic drivers of ABR, arguing that ABR in large part arises from extensive unresolved market (an...
Blog Post
December 16, 2022
In 2020, we opened our end-of-year review by saying that “Not even Dr. Pangloss could put a positive spin on… a historic dumpster fire of a year.” The next year, we described 2021 as “not quite the best of times, not quite the worst of times”, which seemed like progress. But if we take one lesson fr...
Blog Post
December 20, 2021
As the year draws to a close, the temptation to claim wisdom from adversity and experience becomes irresistible. We did it last year, by exploring what we learnt while the world burned around us. 2021 was perhaps a marginal improvement: not quite the best of times, but not quite the worst of times, ...
Blog Post
October 21, 2021
After buying up the World’s vaccine supply to ensure they can protect their own populations, rich countries have found themselves struggling to use the vaccine surpluses they accumulated. One response has been to donate the spare doses to countries who need them more. This is laudable, and countries...
Blog Post
June 14, 2021
Many rich countries pre-ordered vast quantities of COVID-19 vaccines when they were still in development, enough to vaccinate their countries many times over. What is the right ‘price’ to pay for surplus vaccines, as opposed to those newly purchased? And how much of their value should be count...
Blog Post
April 22, 2021
Among the many disparities and inequities that COVID-19 has shone a light upon, the chasm in health outcomes between rich and poor countries is being particularly sharply highlighted. While Israel, the US, the UK, and a handful of high- and upper-middle income countries are charging forward with the...